Department of Neuroscience, University of Torino, Italy.
Acta Neurol Scand. 2013 May;127(5):e28-32. doi: 10.1111/ane.12075. Epub 2013 Jan 11.
Sleep disorders are common in patients with advanced Parkinson's disease (PD). Nocturnal akinesia and sleep fragmentation frequently coexist with daytime sleepiness, influencing daytime functioning. Levodopa/carbidopa intestinal gel (LCIG) infusion has been shown to improve motor complications in advanced PD, and preliminary findings suggest that sleep might improve following LCIG infusion.
To analyze the impact of LCIG infusion on sleep symptoms and daytime sleepiness in patients with PD.
Twelve consecutive patients with PD completed the PD-Sleep-Scale-version-2 (PDSS-2) and the Epworth-Sleepiness-Scale (ESS) at baseline and after 2-4 months of LCIG treatment. Activities of daily living, motor symptoms and complications were assessed with the Unified-PD-rating-Scale section II, III, and IV.
Nocturnal sleep improved substantially in all patients switched to LCIG infusion. PDSS-2 total score and subscores for 'Disturbed sleep', 'Motor symptoms at night', and 'PD symptoms at night' were significantly reduced. ESS measures of daytime sleepiness also improved. Motor complications and activities of daily living improved significantly with LCIG.
Subjective measures of sleep quality and daytime sleepiness improve in patients with advanced PD undergoing LCIG infusion. Further studies with a larger number of patients and polysomnographic recordings are needed to confirm the beneficial effect on sleep and clarify the underlying mechanisms.
睡眠障碍在晚期帕金森病(PD)患者中很常见。夜间运动不能和睡眠碎片化常与白天嗜睡并存,影响白天的功能。左旋多巴/卡比多巴肠凝胶(LCIG)输注已被证明可改善晚期 PD 的运动并发症,初步研究结果表明 LCIG 输注后睡眠可能会得到改善。
分析 LCIG 输注对 PD 患者睡眠症状和白天嗜睡的影响。
12 例连续的 PD 患者在基线时和 LCIG 治疗 2-4 个月后完成 PD 睡眠量表-2(PDSS-2)和 Epworth 嗜睡量表(ESS)。使用统一帕金森病评定量表第二、三、四部分评估日常生活活动、运动症状和并发症。
所有切换到 LCIG 输注的患者夜间睡眠均有显著改善。PDSS-2 总分和“睡眠障碍”、“夜间运动症状”和“夜间 PD 症状”的亚评分均显著降低。ESS 白天嗜睡的测量也有所改善。LCIG 显著改善了运动并发症和日常生活活动。
接受 LCIG 输注的晚期 PD 患者主观睡眠质量和白天嗜睡的测量均有所改善。需要更多患者和多导睡眠图记录的进一步研究来确认对睡眠的有益影响,并阐明潜在的机制。